Immunic highlights multiple sclerosis drug findings at key neurology gathering

Immunic Inc. (NASDAQ:IMUX) presented compelling Phase 2 CALLIPER trial data for its oral therapy, vidofludimus calcium, at ECTRIMS, indicating significant efficacy in slowing disability progression for patients with progressive multiple sclerosis. The drug demonstrated over double the likelihood of physical function improvement and nearly a quarter reduction in disability worsening versus placebo, notably benefiting patients irrespective of active inflammation, suggesting a neuroprotective mechanism. These results, alongside positive long-term data in relapsing-remitting MS, highlight vidofludimus calcium's potential in a high-unmet-need area, with Phase 3 trial results for relapsing disease expected in 2026.

Analysis

Immunic Inc. has presented a significant clinical update for its lead asset, vidofludimus calcium, at the ECTRIMS congress, a key event for neurologists. The Phase 2 CALLIPER trial data demonstrated notable efficacy in progressive multiple sclerosis (PMS), a form of the disease with high unmet medical need. Patients treated with the drug were more than twice as likely to show improved physical function and experienced a nearly 25% reduction in disability worsening risk versus placebo. Crucially, this effect was observed even in patients without active inflammation, lending strong support to the drug's potential as a neuroprotective therapy rather than just an anti-inflammatory one. This finding is further reinforced by its dual mechanism of action, which involves activating the neuroprotective protein Nurr1. The data's selection for the "Best of ECTRIMS" highlights its clinical significance. Furthermore, long-term data from the EMPhASIS study in relapsing-remitting MS, showing over 90% of patients remained free of disability worsening after five years, reinforces the drug's favorable safety and durability profile. The company's pipeline now hinges on two ongoing Phase 3 trials, with results anticipated in 2026, which will be the next major value inflection point.

Key Decisions for Investors

• The compelling Phase 2 data, particularly the novel neuroprotective mechanism in a high-unmet-need population, materially de-risks vidofludimus calcium and strengthens the long-term bullish case for IMUX.
• Investors should now focus on the two ongoing Phase 3 trials, as the results expected in 2026 represent the most critical upcoming catalyst for the company's valuation.
• Given the favorable safety profile and strong efficacy signals, it may be prudent to manage any position to account for potential near-term positive momentum, while remaining cognizant of the binary risk associated with the forthcoming Phase 3 readouts.